advertisement

Topcon

Abstract #22157 Published in IGR 10-4

Intracameral bevacizumab for treatment of iris rubeosis

Liu T
International Journal of Ophthalmology 2008; 8: 1761-1763


AIM: To report the curative effect and safty of intracameral bevacizumab (avastin) in patients with rubeosis iridis. METHODS: Five cases (5 eyes) with iris rubeosis secondary to diabetic retinopathy, retinal periphlebitis (Eales disease) and branch/central retinal vein occlusion, among which 2 cases were silicon oil eyes and were performed intracameral bevacizumab (avastin) 0.03 cc (0.75mg), one case is combined with trabeculectomy, and another with cyclocryosurgery. RESULTS: The rubeosis in all cases disappeared quickly, meanwhile the intraocular pressure decreased to normal range with the help of anti-glaucoma operation and medicine. There are no signs of rubeosis again in the 2-5 months follow-up visits and intraocular pressure were well-controlled. CONCLUSION: Intracameral bevacizumab (avastin) was an effective treatment for rubeosis, especially for some cases that can not be injected to vitreous cavity. Short-term study of intracameral bevacizumab demonstrated rapid regression of rubeosis and well-tolerated injection with no obvious side effects.

Dr. T. Liu, Department of Ophthalmology, No. 3201 Hospital, Hanzhong 723000 Shannxi Province, China. taoliustone@163.com


Classification:



Issue 10-4

Change Issue


advertisement

Topcon